Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tobramycin Clear all
Terminated No phase listed Observational

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TOBI™ Podhaler™ 112 mg inhaled twice daily, Colistimethate 75 mg inhaled two times daily
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
12 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated No phase listed Observational Results available

Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution

NCT02038803
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TOBIpodhaler
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 5, 2026, 4:41 AM EDT
Completed No phase listed Observational

A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies

NCT01319253
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
6 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

NCT02054156
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo, Tobramycin solution for inhalation
Drug
Lead sponsor
Bonnie Ramsey
Other
Eligibility
6 Months to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2009 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional

A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte

NCT00198523
View directory record Official record
Conditions
Eye Infections, Postoperative Complications
Interventions
Prednisolone and Tobramycin, Prednisolone
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Great Bend, Kansas • Boston, Massachusetts • Saint Joseph, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 5, 2026, 4:41 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 5, 2026, 4:41 AM EDT
Not listed No phase listed Observational

Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants

NCT01349738
View directory record Official record
Conditions
Bacteriuria, Urinary Tract Infections, Asymptomatic Infections, Transplantation Infection
Interventions
Antibiotic
Drug
Lead sponsor
Rice, James C., M.D.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

NCT04850313
View directory record Official record
Conditions
Bacterial Corneal Ulcer
Interventions
ProProKera Plus®
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

NCT01270347
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution)
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
99
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 5, 2026, 4:41 AM EDT
Active, not recruiting Phase 3 Interventional

Tobramycin Injection to Prevent Infection in Open Fractures

NCT04964947
View directory record Official record
Conditions
Wound Infection, Fractures, Open, Surgical Site Infection
Interventions
Tobramycin Injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
FTI, AZLI, Placebo, AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2013 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1 Interventional Results available

Inhaled Tobramycin in BPD

NCT04560179
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose, Tobramycin solution for inhalation 300mg dose
Drug
Lead sponsor
Erik Allen Jensen
Other
Eligibility
4 Weeks and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 2 Interventional

A Second Trial of the Abbreviated Protocol Two-Stage Exchange

NCT05607030
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
VT-X7 Treatment System, Two-stage exchange arthroplasty, SOC Antibiotics, Experimental Antibiotics
Combination Product · Procedure · Drug
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Sarasota, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antibiotic Loaded Cement After TKA

NCT05429671
View directory record Official record
Conditions
Total Knee Arthoplasty
Interventions
total knee arthroplasty, Tobramycin, Gentamicin, Antibiotic cement spacer
Procedure · Drug · Device
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 5, 2026, 4:41 AM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty

NCT06383611
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
VT-X7 Treatment System
Combination Product
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Grand Junction, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Phase 4 Interventional Results available

Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

NCT02478710
View directory record Official record
Conditions
Pneumonia, Ventilator-Associated
Interventions
Aerosolized Tobramycin or Vancomycin, Aerosolized Placebo
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

NCT00125346
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 21 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 5, 2026, 4:41 AM EDT
Completed Phase 4 Interventional Results available

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo (for azithromycin), inhaled tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 5, 2026, 4:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

NCT05361941
View directory record Official record
Conditions
Periprosthetic Joint Infections
Interventions
EP Granules with Tobramycin, empty voids
Device
Lead sponsor
Elute, Inc.
Industry
Eligibility
22 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Skokie, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 5, 2026, 4:41 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 5, 2026, 4:41 AM EDT